Medicare AdvantagePrior AuthMedium impact
MA08.184a, Cosibelimab-ipdl (Unloxcyt™)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Jun 1, 2026
We identified it
Jun 19, 2026
Summary
MA08.184a establishes medical necessity criteria for Cosibelimab-ipdl (Unloxcyt™), a newly covered pharmacy agent effective June 1, 2026. The billing team must implement prior authorization requirements and ensure claims include documentation supporting medical necessity criteria outlined in this policy.
Action Required
By May 15, 2026: Billing team must review the full policy text at the provided URL to identify specific medical necessity criteria and HCPCS code(s) for Cosibelimab-ipdl. Update billing system to flag all claims for this drug as requiring prior authorization documentation. Coordinate with providers and pharmacy staff to ensure prescriptions include medical necessity justification before submission. Add this drug to the prior auth checklist in the EMR and billing software. Claims submitted without proper medical necessity documentation will be denied by Medicare Advantage plans.